Literature DB >> 20108445

[Effects of recombinant Balillus Calmette-Guerin secreting IL-12 vaccination on development of T cell subsets in neonatal BALB/c mice].

Yun He1, En-mei Liu, Xi-qiang Yang, Xin Li, Wei Liu.   

Abstract

AIM: To explore the effects of recombinant Balillus Calmette-Guerin secreting IL-12 on the development of spleen T cell subsets of neonatal BALB/c mice.
METHODS: Twenty-four neonatal BALB/c mice were divided 3 groups: Control, BCG, r-BCG groups, which inoculated with BCG and r-BCG intraperiotoneally within 2-3 days after birth. Four weeks later, spleen cells of mice were isolated and the percentage of CD3(+) CD8(+) INF-gamma(+)/CD3(+) CD8(-) IFN-gamma(+)/CD3(+) CD8(+) IL-4(+)/CD3(+) CD8(-) IL-4(+)/ CD4(+) Foxp3(+) T cells, which represent Tc1/Th1/Tc2/Th2/Treg cells respectively were detected by flow cytometry at single cells level, and Th1/Th2, Tc1/Tc2 ratio were calculated.
RESULTS: The percentages of Th1, Tc1 cell of BCG-vaccinated mice, r-BCG -vaccinated mice were significant higher than control mice (P < 0.01), and there was no difference between the two vaccinated groups. The ratio of Th1/Th2, Tc1/Tc2 and total IFN-gamma/IL-4 of two vaccinated groups were higher than control group. The percentages of Treg cells were no difference among the three groups (P > 0.05).
CONCLUSION: Neonatal BCG and r-BCG vaccination can significantly increase Tc1 and Th1 cells and Th1/Th2, Tc1/Tc2 ratio in spleen cells. Neonatal BCG and r-BCG vaccination may have an same effects on development of T cell subsets in neonatal BALB/c mice. The percentage of CD4(+) Foxp3(+) T cells among three groups were no significant difference.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 20108445

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  1 in total

Review 1.  New insights into IL-12-mediated tumor suppression.

Authors:  S Tugues; S H Burkhard; I Ohs; M Vrohlings; K Nussbaum; J Vom Berg; P Kulig; B Becher
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.